December 16, 2021 - December 20, 2021

Supriya Lifescience IPO Review & Recommendations

Dilip Davda, Nirmal Bang and InvestorGain.com have given "Apply" recommendation to Supriya Lifescience IPO. Axis Capital has "Not Rated" the IPO.

Supriya Lifescience IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	3	0	0	0	1
%	75.00	0.00	0.00	0.00	25.00

Supriya Lifescience IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Axis Capital	Not Rated
Dilip Davda	Apply
Nirmal Bang	Apply
InvestorGain.com	Apply

Supriya Lifescience IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Supriya Lifescience IPO is 48. Their analysis recommends May subscribe for the IPO.

Reviewer	Rating Score	Rating
Capital Market	48	May subscribe

Supriya Lifescience IPO Review by Dilip Davda (Apply)

[Dilip Davda] SLL has been making strides with higher top and bottom lines year after year and exporting over 75% of products to more than 86 countries. Based on financial parameters, the issue is attractively priced leaving something on the table across the board. The issue is worth considering for short to long term rewards. Read detail review...

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.